Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022)

The central concept is "mature B‑cell lymphoid leukaemia and small lymphocytic lymphoma", defined as a malignant neoplasm characterised by clonal proliferation of small morphologically mature, non‑functioning lymphoid cells of B‑cell origin, which can present clinically as either a leukaemia or a lymphoma. The definition explicitly includes B‑cell prolymphocytic leukaemia, chronic lymphocytic leukaemia/small lymphocytic lymphoma, and hairy cell leukaemia. It excludes non‑Hodgkin lymphoma other than small lymphocytic lymphoma. The note in subsection 7(2) confirms that small lymphocytic lymphoma and chronic lymphocytic leukaemia are considered a single disease entity with two clinical presentations, reflecting current medical classification.

The second key concept is "relevant service", defined in the dictionary to mean: operational service under the VEA; peacekeeping service under the VEA; hazardous service under the VEA; British nuclear test defence service under the VEA; warlike service under the MRCA; or non‑warlike service under the MRCA. This list is exhaustive; service that does not fall into one of these categories (such as peacetime service under the VEA or MRCA, or service not covered by those Acts) is not relevant service for the purposes of this SoP. For those other types of service, the reasonable hypothesis standard does not apply, and a different SoP (the balance of probabilities version) would govern.

The third core concept is "reasonable hypothesis". This is not defined in this instrument but is a legal standard under the VEA and MRCA. The SoP sets out the factors that must exist as a minimum before a reasonable hypothesis can be said to exist. The RMA has determined, under section 8, that there is sound medical‑scientific evidence that mature B‑cell lymphoid leukaemia and small lymphocytic lymphoma can be related to relevant service. That finding is a condition precedent for making the SoP.

The SoP uses several exposure‑measurement concepts. "ppm‑years" is defined as parts per million multiplied by years of exposure. "8‑hour time‑weighted average" means the averaging of different exposure levels during an average exposure period equivalent to eight hours. This is a standard occupational hygiene metric. The "cumulative equivalent dose" is the total dose of ionising radiation to a particular organ or tissue from external and internal exposure, excluding normal Australian background radiation, calculated according to the ARPANSA guide as in force on 2 August 2017. The SoP also uses "cumulative total of hours" for some agents (benzene, ethylene oxide, 1,3‑butadiene) measured over a continuous period of 5 or 10 years before clinical onset.

Another important concept is the latency period: each factor relating to chemical or radiation exposure has a requirement that the first exposure occurred at least 5 years before clinical onset. This reflects the typical induction period for haematological malignancies. For hepatitis C virus, there is no explicit latency period in the factor text, but chronic infection (at least 6 months) must exist before clinical onset. For the inability to obtain appropriate clinical management factor, it applies only to material contribution to or aggravation of the disease where the disease was suffered or contracted before or during (but did not arise out of) relevant service.

The SoP also introduces the concept of "terminal event" to define death from the disease: it includes proximate causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function, if contributed to by the mature B‑cell lymphoid leukaemia or small lymphocytic lymphoma. This broadens the compensable death outcome beyond direct mortality from the malignancy itself.

The primary persons affected are current and former members of the Australian Defence Force, veterans, members of Peacekeeping Forces, and members of the Forces under the VEA, as well as members under the MRCA. Specifically, persons who have rendered relevant service (operational, peacekeeping, hazardous, British nuclear test defence, warlike, or non‑warlike service) and who subsequently develop mature B‑cell lymphoid leukaemia or small lymphocytic lymphoma may now have a recognised pathway to link their condition to service if they can establish one of the nine factors. Their dependants (for death claims) are also affected because the SoP governs whether a death is taken to be service‑related.

The instrument also affects decision‑makers: the Repatriation Commission, the Military Rehabilitation and Compensation Commission, and the Veterans' Review Board. They are bound to apply the SoP when assessing claims for liability or incapacity under the reasonable hypothesis standard. This means that they must accept that a reasonable hypothesis exists if at least one factor in section 9 is met and that factor is related to the person's relevant service. The SoP displaces any contrary medical opinion on the existence of a hypothesis; the decision‑maker cannot reject a claim solely because the medical evidence does not support a causal link if the factor is proven.

The Repatriation Medical Authority itself is directly affected as the maker of the instrument. It must ensure that the factors are based on sound medical‑scientific evidence. The RMA's determination under section 8 is a statutory precondition.

Medical practitioners who provide reports for veterans' claims are indirectly affected because they need to be aware of the recognised factors to assess whether their patient's condition may be service‑related. For example, a haematologist treating a veteran with chronic lymphocytic leukaemia would need to take an exposure history regarding benzene, ethylene oxide, 1,3‑butadiene, and ionising radiation, and test for hepatitis C virus.

The SoP does not directly affect employers or the general public, but it imposes costs on the Commonwealth budget via increased compensation payments. Taxpayers ultimately bear the cost. The expansion from the 2014 SoP (which covered chronic lymphocytic leukaemia and small lymphocytic lymphoma) to the current broader definition (including B‑cell prolymphocytic leukaemia and hairy cell leukaemia) extends the pool of potential claimants. The inclusion of hepatitis C virus as a factor and the lower threshold for benzene (2,500 hours at 5 ppm, or 10 ppm‑years) compared to earlier standards may increase claim numbers.

The compliance burden for veterans is in proving the factor exists, particularly for chemical exposures where records may be incomplete. For benzene, ethylene oxide, and 1,3‑butadiene, the claimant must show exposure at specified concentrations and durations. For ionising radiation, the claimant must calculate cumulative equivalent dose, which may require expert dosimetry. The SoP does not shift the burden of proof; the claimant still bears the evidentiary burden, but the SoP provides a framework for what evidence is relevant.

The SoP does not create duties or rights directly; it operates within the VEA and MRCA frameworks. However, it gives claimants a right to have their claim assessed using the reasonable hypothesis standard if they render relevant service. The key duty is on the decision‑maker to apply the SoP correctly. Under section 9, if at least one factor exists, the decision‑maker must accept that a reasonable hypothesis has been raised connecting the disease to service. There is no discretion to reject a claim on the basis that the hypothesis is implausible if the factor is established, because the RMA has already determined that the factor is based on sound medical‑scientific evidence.

The claimant has a duty to provide evidence that establishes the factor. For example, to rely on factor (1) (benzene exposure), the claimant must show cumulative exposure of at least 2,500 hours within a continuous 5‑year period, with first exposure at least 5 years before clinical onset, and that the exposure was "being exposed to benzene as specified" (cutaneous contact with liquids >1% benzene, ingestion of such liquids, or inhalation at an 8‑hour TWA exceeding 5 ppm). The claimant must also demonstrate that the exposure occurred during relevant service.

The SoP also includes a duty for decision‑makers to consider whether a factor refers to another injury or disease covered by another Statement of Principles. Section 11 states that if a factor refers to an injury or disease for which an SoP exists under subsection 196B(2), then the factors in that other SoP apply. For example, if a claimant relies on factor (3) (hepatitis C virus), and the hepatitis C was contracted during service, the decision‑maker may need to refer to the SoP for hepatitis C to determine if a reasonable hypothesis exists for that infection. This creates a cascading application of SoPs.

The right to have a claim determined under the reasonable hypothesis standard is limited to those with relevant service. For persons with service that is not relevant (e.g., peacetime service only), the claim falls under the balance of probabilities standard, and a different SoP (if any) would apply. This distinction affects the evidentiary burden: reasonable hypothesis is easier to satisfy than balance of probabilities.

There is no duty on the RMA to reconsider the SoP, but the VEA provides for review if new sound medical‑scientific evidence arises. The SoP itself does not contain any sunset clause, but it can be amended or revoked by a later instrument.

The SoP does not create any rights for third parties, such as family members, except in death claims. In death claims, the dependant must show that the death was from mature B‑cell lymphoid leukaemia or small lymphocytic lymphoma, as defined in subsection 7(3), and that the disease was connected to the veteran's service.

This SoP does not contain any penalty provisions. It is not a regulatory instrument imposing obligations on individuals or entities with sanctions for non‑compliance. Instead, it is an evidentiary and procedural instrument used in the administration of veterans' compensation. Enforcement occurs through the claims system: a decision‑maker who fails to apply the SoP correctly may have their decision set aside on review by the Veterans' Review Board, the Administrative Appeals Tribunal, or the Federal Court.

The relevant penalties for making false statements in a claim are found in the VEA and the Criminal Code, not in this SoP. Section 204 of the VEA makes it an offence to make a false or misleading statement in connection with a claim, carrying a penalty of imprisonment. Similarly, the MRCA contains offences for fraud. These penalties apply regardless of the SoP. The SoP itself does not create any new criminal or civil penalties.

If a decision‑maker misapplies the SoP, the remedy is administrative review, not a penalty. The Veterans' Review Board can set aside a decision and substitute a new decision that correctly applies the SoP. The SoP is binding on decision‑makers, but there is no mechanism in the instrument to penalise a decision‑maker for error. The system relies on the internal and external merits review process.

The SoP may affect the enforcement of other laws indirectly. For example, if a claim is granted based on benzene exposure during service, the Department of Defence may face pressure to improve toxic exposure monitoring, but that is not a direct enforcement consequence of this SoP.

The Repatriation Medical Authority is subject to judicial review under the Administrative Decisions (Judicial Review) Act 1977 if it makes a SoP that is ultra vires or procedurally flawed. However, the SoP itself does not mention any such review. The instrument is a legislative instrument, and disallowance by the Parliament is possible under the Legislation Act 2003. Disallowance would nullify the SoP, but that is a political enforcement mechanism, not a legal penalty.

The SoP is made under subsection 196B(2) of the VEA, and it operates within the broader statutory schemes of the VEA and the MRCA. It interacts with the definition of "relevant service" in both Acts, as defined in the dictionary. The SoP applies to claims under section 120A of the VEA (reasonable hypothesis for operational service) and section 338 of the MRCA (reasonable hypothesis for warlike and non‑warlike service). For claims made under section 120A, the standard is that the decision‑maker must be satisfied beyond reasonable doubt that there is no sufficient ground for determining that the disease is service‑related, but if a reasonable hypothesis is raised, the claim must succeed unless the decision‑maker can negative the hypothesis. The SoP defines what constitutes a reasonable hypothesis.

The SoP specifically repeals the 2014 SoP concerning chronic lymphocytic leukaemia and small lymphocytic lymphoma. That repeal means the earlier instrument no longer applies, even to claims that arose before 19 September 2022, because section 5 applies the instrument to claims to which section 120A of the VEA or section 338 of the MRCA applies. Generally, the instrument in force at the time of decision applies, not the instrument in force at the time of the claim or onset. This is consistent with the principle that procedural and evidentiary rules operate retrospectively unless the legislature provides otherwise.

Section 11 of the SoP provides for interaction with other Statements of Principles: if a factor in this SoP refers to an injury or disease covered by another SoP, the factors in that other SoP apply. For example, factor (3) requires "chronic infection with hepatitis C virus before clinical onset". If a claimant seeks to establish that the hepatitis C infection itself is service‑related, they would need to rely on the SoP for hepatitis C (if one exists) to raise a reasonable hypothesis for that infection. This creates a chain of causation: the claimant must show that the hepatitis C is connected to service via its own SoP, and then that the hepatitis C caused the leukaemia. This can increase the evidentiary complexity.

The SoP also interacts with the military compensation provisions in the MRCA. Section 338 of the MRCA applies the same SoP framework as the VEA for warlike and non‑warlike service. For peacetime service under the MRCA (where the standard is balance of probabilities), a different SoP made under subsection 196B(8) would apply. The RMA typically determines concurrent SoPs for the same disease under both subsections (2) and (8). This SoP is only the (2) version; there may be a separate SoP for balance of probabilities (No. 79 of 2022 presumably). That would affect the same disease but with possibly different factors or thresholds. This SoP does not incorporate the balance of probabilities SoP.

The SoP defines "death from mature B‑cell lymphoid leukaemia and small lymphocytic lymphoma" to include a terminal event contributed to by the disease. This interacts with the definition of "dependants" in the VEA and MRCA for death benefits. It may also interact with the Safety, Rehabilitation and Compensation Act 1988 for Defence civilians, but that Act uses a different test and is not covered by this SoP.

State workers' compensation laws are not directly affected, but a veteran who receives compensation under the VEA or MRCA for this disease cannot also receive state workers' compensation for the same condition due to statutory offsets. The SoP does not address this, but it is a practical interaction.

The SoP itself has not been amended since its commencement on 19 September 2022. However, it repeals the existing SoP No. 84 of 2014 (concerning chronic lymphocytic leukaemia and small lymphocytic lymphoma). That repeal is itself a form of amendment to the regulatory landscape. The 2014 SoP is explicitly repealed in full. The instrument cites the Federal Register of Legislation number F2014L01146 for that earlier instrument. This repeal means that any claims decided after 19 September 2022 must apply the new SoP, even if the disease or service occurred before that date. The 2014 SoP no longer has legal effect.

The source text does not mention any other amendments to this instrument. The SoP is a standalone instrument that does not amend any other legislation. It is made under the VEA but does not amend the VEA itself.

It is worth noting that the SoP references the "Guide to calculation of 'cumulative equivalent dose' ... Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017". This Guide may be amended from time to time, but the SoP fixest the version as at 2 August 2017. This creates a static reference, so if ARPANSA updates its methodology, this SoP would need to be amended to incorporate the change. The same issue applies to the dictionary definitions of "being exposed to benzene as specified" and others, which refer to concentrations and thresholds that do not change automatically.

The SoP was made on 23 August 2022 and commences on 19 September 2022. There is no indication of any transitional provisions. The repeal of the 2014 SoP is effective the same date. The instrument does not state what happens to claims that were already determined under the 2014 SoP; presumably they are final unless reopened on a different basis.

The source text does not mention any litigation history. This SoP is a legislative instrument that has been in force only since September 2022. As of the date of this analysis, there are no recorded court or tribunal decisions interpreting this specific instrument in the public domain (the source does not provide any). However, litigation may exist under the predecessor SoP (No. 84 of 2014) or under the general framework of the VEA. The fact that litigation is not discussed in the instrument is consistent with the nature of a SoP: it is a delegated instrument that sets out medical‑scientific factors, and it is not a court decision. Any disputes about its application would be determined by the Veterans' Review Board or the Administrative Appeals Tribunal, and appeals on questions of law to the Federal Court are possible. This deep dive cannot supply case law beyond what the source provides, and none is given.

The SoP itself could be challenged in judicial review proceedings on grounds such as procedural error, unreasonableness, or error of law. However, such challenges are rare and this instrument has not been the subject of any reported challenge. Given that the RMA followed its statutory process, the SoP is likely to be held valid.

Several provisions contain traps for the unwary.

First, the definition of "mature B‑cell lymphoid leukaemia and small lymphocytic lymphoma" in subsection 7(2) excludes non‑Hodgkin lymphoma other than small lymphocytic lymphoma. This means that a veteran with a diagnosis of follicular lymphoma or mantle cell lymphoma cannot rely on this SoP, even if those conditions are also B‑cell neoplasms. The note in subsection 7(2) confirms that small lymphocytic lymphoma and chronic lymphocytic leukaemia are considered one entity, but other low‑grade B‑cell lymphomas are not covered. A misdiagnosis could lead to the wrong SoP being applied.

Second, the latency requirement for chemical and radiation factors (first exposure at least 5 years before clinical onset) is strict. If exposure occurred 4 years before diagnosis, the factor cannot be satisfied, even if the total hours or ppm‑years are met. This can be a trap for claimants with late‑onset disease and service in the 5 years before diagnosis.

Third, the exposure thresholds are defined in the dictionary with specific concentration cut‑offs. For benzene, the 8‑hour time‑weighted average must exceed 5 ppm for the inhalation route; for ethylene oxide, at least 1.5 ppm; for 1,3‑butadiene, greater than 10 ppm. Service records may not capture concentrations at that level; often only presence of a chemical is recorded, not the concentration. Without monitoring data, the claimant may need to rely on expert modelling, which is costly and may be contested.

Fourth, "cumulative equivalent dose" for ionising radiation is calculated in accordance with the ARPANSA guide as in force on 2 August 2017. That guide is an external document. If a claimant's radiation exposure involves multiple sources (e.g., nuclear test participation plus medical procedures), the calculation must follow that specific methodology. Normal background radiation in Australia is excluded, which is a nuance that could reduce the dose count.

Fifth, factor (9) (inability to obtain appropriate clinical management) applies only to material contribution to or aggravation of the disease where the disease was suffered or contracted before or during (but did not arise out of) relevant service. This means it cannot be used to establish initial liability for the disease; it only applies to worsening. A claimant who already had the disease before service and then could not get treatment due to service may use this factor, but the disease must have been pre‑existing and not service‑caused. The wording in subsection 10(2) is restrictive.

Sixth, section 11 introduces a cascading effect: if a factor refers to an injury or disease covered by another SoP, the factors in that SoP apply. This means a claimant relying on hepatitis C virus must also satisfy the SoP for hepatitis C (if it exists). That SoP may have additional factors and latency requirements that are not obvious from this instrument. The claimant cannot simply show hepatitis C infection; they must show that the hepatitis C is itself related to service via its own reasonable hypothesis SoP.

Seventh, the SoP applies only to claims under section 120A of the VEA or section 338 of the MRCA. If a claim is made under a different provision (e.g., section 120B for peacetime service), this SoP does not apply. Claimants and practitioners must confirm the correct standard and corresponding SoP.

Eighth, the dictionary definition of "relevant service" excludes warlike service under the VEA (which is covered by "operational service") but includes warlike service under the MRCA. This mirroring is intentional but can cause confusion for those who served after 1 July 2004 under the MRCA.

For a veteran or member seeking to establish a claim for mature B‑cell lymphoid leukaemia or small lymphocytic lymphoma, the first step is to obtain a confirmed diagnosis that fits the definition in subsection 7(2). The diagnosis should be from a haematologist or oncologist and specify the exact subtype. A diagnosis of chronic lymphocytic leukaemia or hairy cell leukaemia qualifies; a diagnosis of diffuse large B‑cell lymphoma does not.

Second, the claimant must identify which factor(s) in section 9 may apply based on their service history. Common exposure pathways include: benzene from fuel handling or solvent use; ethylene oxide from sterilisation of surgical instruments in medical service; 1,3‑butadiene from fuel distribution or rubber manufacturing; ionising radiation from nuclear test participation, radiological procedures, or aircrew duties; hepatitis C virus from blood transfusions or needle‑stick injuries; or inability to obtain appropriate clinical management for a pre‑existing condition during service.

Third, the claimant must gather evidence to meet the specific exposure thresholds. For benzene under factor (1), they need to show cumulative exposure of at least 2,500 hours within a continuous 5‑year period, with exposure at an 8‑hour TWA above 5 ppm, or cutaneous contact with liquids >1% benzene. Service records, unit histories, and occupational hygiene reports may help. If direct monitoring data is unavailable, a reconstruction by an industrial hygienist may be necessary. For factor (2), the cumulative dose must exceed 10 ppm‑years, calculated by multiplying average concentration by years.

For ethylene oxide and 1,3‑butadiene, similar hour and ppm‑year thresholds apply. For ionising radiation, the claimant must calculate cumulative equivalent dose to the bone marrow of at least 0.1 sievert, using the ARPANSA Guide dated 2 August 2017. This may require a radiation dosimetry expert.

For hepatitis C virus, the claimant must show a chronic infection (at least 6 months) confirmed by laboratory testing, and that the infection occurred before clinical onset of the leukaemia. The hepatitis C infection itself must be related to service, likely via its own SoP.

Fourth, the claimant must demonstrate that the exposure or infection occurred during relevant service (as defined) and that the first exposure for chemical/radiation factors was at least 5 years before clinical onset. The clinical onset date is critical and should be established by medical records.

Fifth, if the claim is made after the disease has progressed, the claimant should ensure that any death certificate lists mature B‑cell lymphoid leukaemia or small lymphocytic lymphoma as a contributing cause, or that a terminal event (pneumonia, respiratory failure, etc.) was contributed to by the disease.

Sixth, the practitioner assisting the claimant should check whether any factor refers to another injury or disease with its own SoP. For example, hepatitis C or hepatitis B (not mentioned) would require a separate SoP. They should obtain that SoP and ensure its factors are also met.

Seventh, for claims involving inability to obtain appropriate clinical management (factor 9), the claimant must show that the disease was suffered or contracted before or during service (but not arising out of service) and that service prevented appropriate management, materially contributing to aggravation. This is a distinct pathway that does not require exposure to a toxic agent.

Eighth, the decision‑maker must apply section 10: each factor must be related to the relevant service. So the exposure or condition must have occurred during service, not just in the civilian context.

Ninth, the claimant should file the claim with the Department of Veterans' Affairs or the Military Rehabilitation and Compensation Commission, using the appropriate claim form for the relevant service type. The decision‑maker will then assess the claim against this SoP. If the decision is unfavourable, the claimant can seek merits review at the Veterans' Review Board or the AAT.

Tenth, all parties should be aware that the SoP is binding. If the claimant meets a factor, the decision‑maker cannot reject the claim on the basis that other medical evidence contradicts a causal link. The only basis for rejection would be if the decision‑maker can negative the hypothesis (e.g., show that the exposure did not occur, or that the disease is not the defined kind). The SoP creates a presumption that the factor is sufficient to raise a reasonable hypothesis.